Nelitolimod clinical trials
Also written SD-101.
Includes 4 studies of Nelitolimod sodium.
How each study uses nelitolimod is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nelitolimod studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2014 (4)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 11
Scioderm, Inc. (4) · Dynavax Technologies Corporation (4) · TriSalus Life Sciences, Inc. (3) · Robert Lowsky (3) · Ronald Levy (2) · University of California, Davis (2) · Paradigm Therapeutics (2) · University of California, San Diego (1)
Often tested with
Tested in the same studies.
BMS-986178 (2) · Epacadostat (1) · Trastuzumab (1) · Ganitumab (1) · Ado-Trastuzumab Emtansine (1) · Pertuzumab (1) · STA 9090 (1) · Veliparib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 2 in phase 3
Studies that test nelitolimod, phase 3 first.
- May 2027Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis BullosaPhase 3 · Paradigm Therapeutics
- Sep 2027An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis BullosaPhase 3 · Paradigm Therapeutics
- Sep 2027Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic AdenocarcinomaPhase 1 · TriSalus Life Sciences, Inc.
- Nov 2027INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastasesEarly Phase 1 · Northwell Health
Studies
Open first, then newest update. How each study uses nelitolimod is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 25
- Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis BullosaRecruitingPhase 3Paradigm TherapeuticsNCT07482787Written as SD-101 Dermal Cream (6%)
- An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis BullosaNot yet recruitingPhase 3Paradigm TherapeuticsNCT07482813Written as SD-101 Dermal Cream (6%)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as SD-101 + Pembrolizumab
- INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastasesRecruitingEarly Phase 1Northwell HealthNCT07172282Written as Nelitolimod
- Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and TremelimumabActive, not recruitingPhase 1University of California, San DiegoNCT06710223Written as SD-101
- Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADTCompletedPhase 2David OhNCT03007732Written as SD-101
- Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver TumorsTerminatedPhase 1/2TriSalus Life Sciences, Inc.NCT05220722Written as SD-101
- Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal MelanomaTerminatedPhase 1TriSalus Life Sciences, Inc.NCT04935229Written as SD-101
- Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic AdenocarcinomaActive, not recruitingPhase 1TriSalus Life Sciences, Inc.NCT05607953Written as SD-101
- TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin LymphomasCompletedPhase 1Ronald LevyNCT03410901Written as TLR9 Agonist SD-101
- TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular LymphomaCompletedPhase 1/2Robert LowskyNCT02927964Written as TLR9 Agonist SD-101
- SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid MalignanciesCompletedPhase 1Ronald LevyNCT03831295Written as TLR9 Agonist SD-101
- SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic CancerCompletedPhase 1University of California, DavisNCT04050085Written as TLR9 Agonist SD-101
- UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With LymphomaCompletedPhase 1/2University of California, DavisNCT03322384Written as SD-101
- A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedPhase 1/2Dynavax Technologies CorporationNCT02521870Written as SD-101(1)
- Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell LymphomaTerminatedPhase 1/2Dynavax Technologies CorporationNCT02266147Written as SD-101
- ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis BullosaCompletedPhase 3Scioderm, Inc.NCT02384460Written as SD-101-6.0 cream
- Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis BullosaCompletedPhase 2Scioderm, Inc.NCT02014376Written as SD-101 dermal cream (3%)
- A Phase I/II Study of Intratumoral Injection of SD-101CompletedPhase 1/2Robert LowskyNCT02254772Written as SD-101
- Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis BullosaTerminatedPhase 2Scioderm, Inc.NCT02090283Written as SD-101 dermal cream (6%)
Codes
What other systems call nelitolimod · ClinicalTrials.gg INT016748
- UNII (FDA) H5RNU52ZKKNELITOLIMODOne source FDA
- NCI Thesaurus C74084NelitolimodOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | H5RNU52ZKK | NELITOLIMOD | One source FDA |
| NCI Thesaurus | C74084 | Nelitolimod | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.